GlassScriptPhysician profile
Muhammad Arbab Ali
NPI 1730355850
$53,593.84
in general payments reported to CMS, 2019-2025
37 companies · $19K in 2025
The $19K reported for 2025 was more than what 97% of Nephrology (Internal Medicine) providers received nationally (typical 2025 total: $311).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $615 · 2022: $844 · 2023: $8,287 · 2024: $25K · 2025: $19K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $49K · Food and Beverage: $2,985 · Travel and Lodging: $452.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $48,697.50 |
| Food and Beverage | $2,985.18 |
| Travel and Lodging | $452.20 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $19,229.50 | 2022-2025 | Jardiance, Mounjaro, Zepbound |
| Bayer Healthcare Pharmaceuticals INC. | $18,855.42 | 2021-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $12,808.89 | 2021-2025 | Jardiance |
| Astrazeneca Pharmaceuticals LP | $567.62 | 2021-2025 | Farxiga |
| Amgen INC. | $371.73 | 2021-2025 | Krystexxa, Repatha, Otezla |
| Horizon Therapeutics Plc | $258.30 | 2021-2023 | Krystexxa |
| Fresenius USA Marketing, INC. | $167.87 | 2021-2025 | Velphoro, Korsuva, Velphoro |
| Calliditas Therapeutics US INC. | $148.03 | 2022-2025 | Tarpeyo |
| Sanofi-Aventis U.S. LLC | $129.95 | 2021-2022 | |
| Corcept Therapeutics | $127.98 | 2023-2024 | Korlym |
| Novo Nordisk INC | $100.52 | 2021-2025 | Ozempic, Rybelsus |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $78.08 | 2023-2024 | Xifaxan |
| Vifor Pharma, INC. | $74.22 | 2021-2023 | Veltassa |
| Exact Sciences Corporation | $52.52 | 2023 | Cologuard Collection Kit |
| Takeda Pharmaceuticals U.S.A., INC. | $50.81 | 2021-2022 |
Show all 37 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Indivior INC. | $50.60 | 2025 | Sublocade |
| Dynavax Technologies Corporation | $46.30 | 2024 | Heplisav-B |
| Novartis Pharmaceuticals Corporation | $44.35 | 2021-2023 | |
| Axsome Therapeutics, INC. | $38.65 | 2024 | Auvelity |
| Amarin Pharma, INC. | $34.19 | 2021 | |
| Eisai INC. | $31.44 | 2025 | |
| Janssen Pharmaceuticals, INC | $29.63 | 2021-2022 | |
| Pfizer INC. | $28.69 | 2023 | |
| Nestle Healthcare Nutrition INC. | $28.63 | 2022 | |
| Teva Pharmaceuticals USA, INC. | $28.31 | 2022 | |
| Ultragenyx Pharmaceutical INC. | $24.69 | 2022 | |
| Radius Health, INC. | $23.48 | 2024 | Tymlos |
| Biohaven Pharmaceuticals, INC. | $21.95 | 2021 | |
| Abbott Laboratories | $20.49 | 2025 | Freestyle Libre 3 |
| Astellas Pharma US INC | $19.74 | 2021 | |
| Otsuka America Pharmaceutical, INC. | $15.90 | 2021 | |
| Idorsia Pharmaceuticals US INC | $15.63 | 2023 | Quviviq |
| Mylan Specialty L.P. | $15.36 | 2021 | |
| Lantheus Medical Imaging, INC. | $15.19 | 2024 | |
| Merck Sharp & Dohme LLC | $14.35 | 2021 | |
| Kowa Pharmaceuticals America, INC. | $13.15 | 2022 | |
| Alexion Pharmaceuticals, INC. | $11.68 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Muhammad Ali listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.